COMPASS®
COMPASS® Hematopathology Services is a streamlined and personalized lab workup to help inform effective patient care management by providing diagnostic clarity to complex hematologic malignancies and prognostic and predictive information.
Image
IDHNow for AML Sponsored Testing Program
NeoGenomics has partnered with Servier to offer eligible acute myeloid leukemia (AML) patients a rapid IDH1/2 test by polymerase chain reaction (PCR) with a 3- to 5-day turnaround time to help guide your treatment decisions.
Patient eligibility criteria:
- Patient has newly diagnosed AML, not previously treated
- Patient does not have a known IDH1 mutation from a previous test
- Patient lives and receives treatment in the United States or a US territory
- Patient has not previously been tested under this program
Image
My COMPASS® test results provided definitive answers both on my diagnosis and my prognosis so that I could spend more time with my family.